GATA-4 and Serum Response Factor Regulate Transcription of the Muscle-specific Carnitine Palmitoyltransferase I beta  in Rat Heart*

Meredith L. MooreDagger , Guo-Li WangDagger , Narasimhaswamy S. Belaguli§, Robert J. Schwartz§, and Jeanie B. McMillinDagger

From the Dagger  Department of Pathology and Laboratory Medicine, Medical School, University of Texas-Houston Health Science Center and the § Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030

Received for publication, October 13, 2000, and in revised form, October 17, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Transcriptional regulation of nuclear encoded mitochondrial proteins is dependent on nuclear transcription factors that act on genes encoding key components of mitochondrial transcription, replication, and heme biosynthetic machinery. Cellular factors that target expression of proteins to the heart have been well characterized with respect to excitation-contraction coupling. No information currently exists that examines whether parallel transcriptional mechanisms regulate nuclear encoded expression of heart-specific mitochondrial isoforms. The muscle CPT-Ibeta isoform in heart is a TATA-less gene that uses Sp-1 proteins to support basal expression. The rat cardiac fatty acid response element (-301/-289), previously characterized in the human gene, is responsive to oleic acid following serum deprivation. Deletion and mutational analysis of the 5'-flanking sequence of the carnitine palmitoyltransferase Ibeta (CPT-Ibeta ) gene defines regulatory regions in the -391/+80 promoter luciferase construct. When deleted or mutated constructs were individually transfected into cardiac myocytes, CPT-I/luciferase reporter gene expression was significantly depressed at sites involving a putative MEF2 sequence downstream from the fatty acid response element and a cluster of heart-specific regulatory regions flanked by two Sp1 elements. Each site demonstrated binding to cardiac nuclear proteins and competition specificity (or supershifts) with oligonucleotides and antibodies. Individual expression vectors for Nkx2.5, serum response factor (SRF), and GATA4 enhanced CPT-I reporter gene expression 4-36-fold in CV-1 cells. Although cotransfection of Nkx and SRF produced additive luciferase expression, the combination of SRF and GATA-4 cotransfection resulted in synergistic activation of CPT-Ibeta . The results demonstrate that SRF and the tissue-restricted isoform, GATA-4, drive robust gene transcription of a mitochondrial protein highly expressed in heart.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Expression of nuclear and mitochondrial encoded expression of respiratory chain subunits occurs despite physical separation of transcriptional events within separate genomes. Stimulation and coordination of mitochondrial gene expression from these two sites is accomplished by the nuclear respiratory factors, NRF-1 and NRF-2 (1, 2). Using electrical stimulation to produce hypertrophic growth of neonatal cardiac myocytes, the transcriptional activation of cytochrome c is preceded by induction of NRF-1 mRNA (3). This observation is consistent with NRF-1 induction as a prerequisite for synthesis of respiratory chain components. These basic insights into cellular factors that link nuclear events to mitochondrial gene activation are critical for adaptation to environmental stresses and the necessity for enhanced energy production.

In contrast to subcellular coordination of mitochondrial biogenesis and respiratory chain synthesis, less is known concerning tissue-specific transcriptional regulation of nuclear encoded genes involved in energy metabolism. These genes are particularly important in cardiac muscle where contractile activity must be supported by a high rate of aerobic ATP production. There are examples of muscle- or heart-specific mitochondrial proteins that contain sites for ubiquitous transcription factors as well as striated muscle-specific motifs in the proximal promoter, e.g. muscle-specific cytochrome oxidase genes (4). Increases in contractile activity induced by electrical stimulation of neonatal rat cardiac myocytes in culture results in increased mRNA levels of the striated muscle-specific, energy-metabolizing enzymes, carnitine palmitoyltransferase I beta  (CPT-Ibeta )1 (3), and adenylate-succinate synthase I, a component of the purine nucleotide cycle (5).

CPT-Ibeta (the muscle isoform) has been cloned and is the predominant isoform in rat heart and the sole enzyme expressed in skeletal muscle (6). CPT-Ialpha is expressed in most tissues, including the heart. The latter isoform is present at very low levels in the adult cardiac myocyte and is absent in skeletal muscle (6). CPT-I is an example of an enzyme for which the isoforms are very different kinetically. The muscle isoform exhibits an affinity for carnitine that is at least an order of magnitude higher in Km and a KI for malonyl-CoA that is an order of magnitude lower than the KI measured for CPT-Ialpha (6). High expression of the muscle isoform of CPT-I is characteristic of adult heart, so that this particular isoform appears adapted for efficient derivation of energy from long chain fatty acids in an active contracting myocyte.

Very little is known about the heart-specific elements that drive transcription of CPT-Ibeta in heart. Recent work has demonstrated the presence of a fatty acid response element (FARE) in the human CPT-Ibeta promoter (7). After exposing neonatal rat cardiac myocytes to serum-free conditions, addition of exogenous oleate increases expression of the human CPT-Ibeta reporter gene 8-20-fold and CPT-Ibeta mRNA levels rise 4-5-fold (7). Peroxisome proliferator-activated receptor alpha  and the retinoid X receptor act to activate CPT-Ibeta through the FARE site. Peroxisome proliferator-activated receptor alpha  may also play a pivotal role in the expression of enzymes of beta -oxidation (8). The physiological impact of fatty acid induction of CPT-Ibeta in heart is less certain since cardiac CPT-I is resistant to fasting, a condition that enhances serum fatty acid concentrations (9, 10).

We hypothesized that factors that increase expression of tissue specific proteins involved in contractility and energy-utilizing reactions in heart would also be important in regulating the expression of an enzyme involved in transformation of its major energy substrate, long chain fatty acids. Our studies demonstrate for the first time that CPT-Ibeta is regulated by the muscle-specific factor, GATA-4, and by combinatorial interactions between GATA-4 and the nuclear factor, serum response factor (SRF). Interaction between MADS box and C4 zinc finger proteins represents a novel coregulator mechanism of the cardiac actin promoter (11). SRF is especially abundant in embryonic and adult cardiac, skeletal and smooth muscle cells (12-15). The recent homologous recombinant knockout of the murine SRF gene locus demonstrated that SRF is absolutely required for the appearance of mesoderm and muscle lineages during mouse embryogenesis (12). The identification of CPT-Ibeta as a GATA-4-dependent gene that is coactivated by SRF is the first suggestion that this paradigm may represent an important mechanism by which expression of cardiac specific genes is synchronized between subcellular compartments.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture and Transfections-- Primary cultures of neonatal rat cardiac myocytes were prepared as described previously (16). Cells were plated at a density of 6 × 105 cells/well in six-well plates (Primeria, Fisher), and maintained in Dulbecco's modified Eagle's medium (DMEM, CellGro, Fisher) with 1% penicillin/streptomycin (Life Technologies, Inc.) and 10% calf serum (HyClone Laboratories, Inc.). The cells were incubated at 37o in the presence of 95% O2 and 5% CO2 for 36 h before transfection. Myocytes were transfected using calcium phosphate precipitation in the presence of serum as described previously (18). The calcium phosphate precipitate contained 1.0 µg of CPT-Ibeta firefly luciferase vector and 0.25 µg of a CMV-driven Renilla luciferase expression vector (Promega) as a control for transfection efficiency. Six hours following transfection, the myocytes were washed twice with phosphate-buffered saline and maintained in DMEM with serum for an additional 48 h. For treatment with oleic acid, the myocytes were transfected with the CPT-Ibeta (-318/+80) reporter gene and maintained in DMEM + serum for 12 h, washed with phosphate-buffered saline and incubated in serum-free DMEM ± 0.5 mM oleate (2:1 molar ratio oleate:bovine serum albumin) for an additional 24-30 h. CV-1 monkey kidney fibroblasts (ATCC no. CCL-70) were maintained as above but were trypsinized 24 h before transfection and plated to reach 85% confluence by the start of the experiment. CV-1 cells were transfected using LipofectAMINE Plus reagent system (Life Technologies, Inc.) in serum-free medium. After 3 h, the transfection medium was replaced with fresh serum-containing medium for 48 h. Cotransfections included 1.0 µg of the wild-type, truncated, or mutant CPT-Ibeta firefly luciferase reporter constructs and various combinations of the following CMV expression vectors: 0.4 µg of Nkx2.5, 0.4 µg of GATA-4, 0.1 µg of SRF, 0.1 µg of SRF-Delta C, and 0.1 µg of SRF-pm. Total DNA for each transfection was corrected to a final concentration of 2.0 µg by addition of empty CMV vector. Total protein in each well was measured using the BCA protein assay reagent kit (Pierce). CPT-Ibeta firefly luciferase was corrected for protein and normalized to that of the CMV/Renilla expression for each separate experiment.

Electrophoretic Mobility Shift Assays (EMSAs)-- Nuclear extracts from primary rat neonatal cardiac myocytes were prepared as described previously (17). Double-stranded DNA probes containing sequences from the rat CPT-Ibeta promoter were synthesized by Operon Technologies, Inc. (Alameda, CA) as shown in Table I. EMSA reaction mixtures included 2-15 µg of nuclear extract, 25 mM Hepes, 100 mM KCl, 0.1% Nonidet P-40 (v/v), 1 mM dithiothreitol, 5% glycerol, and 50 ng of poly(dI·dC) as a nonspecific competitor in a 20-µl reaction volume. After incubation for 10 min at room temperature, 0.3 ng of radiolabeled probe was added and the reaction incubated for 20 min. When included, specific antibodies (Santa Cruz) or 100-fold molar excess of cold probe was added during the first incubation. Protein-DNA complexes were separated on a 4% nondenaturing polyacrylamide gel at 25 °C.

Plasmids and Constructs-- Construction of the rat CPT-Ibeta promoter fragment -391/+80 has been reported previously (18). The expression vector pCMV-Nkx 2.5 was a gift from Dr. Janet Mar. Construction of the expression vectors for pCGN-SRF, pCGN-SRFpm, pCGN-SRFDelta C, and pCDNA3-GATA-4 has been described (15). A series of CPT-Ibeta promoter constructs with the 5' end between -315 and -31 and the 3' end from -1 to +80 were created by PCR amplification from the plasmid template, -361/+80. Specific primers were designed with an artificial restriction site and the desired region of the rat CPT-Ibeta promoter. For deletion of the MEF2 region contained in the -306/+80 construct, 10 bp (-281 to -270) were deleted from the artificial primer. The PCR products were restricted and cloned into the multiple cloning site of the promoterless firefly luciferase vector, pGL3 basic (Promega, Madison, WI). The inserted CPT-Ibeta fragment in each construct was confirmed by DNA sequencing. The Renilla expression vector, pRL, was purchased from Promega. Mutations were introduced to the -391/+80 CPT-I construct with the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). Briefly, high performance liquid chromatography-purified primers containing the desired mutation were used in concert with the high fidelity polymerase Pfu-turbo for PCR amplification of the -391/+80 plasmid. Wild-type template was digested with DpnI, and the remaining mutated product was transformed into Escherichia coli and sequenced for correct insertion of the mutant primer.

Quantification of CPT-Ibeta Transcripts-- Specific quantitative assay of rat CPT-Ibeta was performed using real time PCR (7700 Prism, PerkinElmer Life Sciences) based on hydrolysis of a specific fluorescent probe at each amplification cycle by the endonuclease activity of Tac polymerase as described previously (19). The sequence for the muscle-specific CPT-I was obtained from GenBankTM (accession no. D43623, nucleotide numbers 869-889 (forward primer) and 932-952 (reverse primer)). The level of transcripts for the constitutive housekeeping gene product, cyclophilin, was quantitatively measured for each sample to control for sample-to-sample differences in RNA concentrations. The PCR data are reported as the number of transcripts per number of cyclophilin mRNAs (19).

Statistics-- Each experiment was performed in triplicate, and the reported values represent the mean of three to five separate cultures ± standard error. The significance of the differences was determined using Student's t test for nonpaired and paired variates (SigmaPlot statistics software).


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

A region within 391 bases 5'of the first exon is sufficient to drive the heart-specific expression of the CPT-Ibeta luciferase reporter gene (18). By normalizing the -391/+80 reporter construct to 1.00, the ratio of the larger genomic fragment, -1188/+80, to -391/+80 is 0.93 ± 0.075. Therefore, we conclude that the promoter elements that regulate CPT-Ibeta expression to the heart are within 390 bp of the transcription start site. A FARE was located in the rat gene at -303 to -296. When 0.5 mM oleic acid (2:1 molar ratio with bovine serum albumin) was added to serum-free medium and neonatal cardiac myocytes cultured for 24-30 h, CPT-Ibeta /luciferase expression was increased from 0.63 ± 0.02 relative luciferase units (in the absence of oleate) to 1.88 ± 0.02 in the presence of oleate. Partial deletion of this region (Delta  bases -301 to -293) resulted in a diminished fatty acid effect, i.e. 0.80 ± 0.01 relative luciferase units (in the presence of oleate) from 0.65 ± 0.06 (in the absence of oleate). Electrophoretic mobility shift assays of this region (Table I) demonstrated binding of myocyte nuclear protein to this site, and this binding was competed by 100- fold excess of cold oligonucleotides and antibodies to the binding factor COUP-TF (20), but not by mutant oligonucleotides (data not shown).


                              
View this table:
[in this window]
[in a new window]
 
Table I
Oligonucleotides for EMSA and reporter gene analysis
Double-stranded oligonucleotides were synthesized for use in DNA EMSAs. The consensus sequences for factor binding are underlined and the mutational changes shown in capitals. The quick-change primers represent the sequence-specific mutations, shown in capitals, of the indicated sites used for transfection studies of the luciferase reporter gene.

To map the regions in the CPT-Ibeta gene that influence expression of the luciferase reporter construct, -391/+80 was progressively deleted from the 5' end and analyzed for luciferase expression following transfection into neonatal cardiac myocytes (Fig. 1). Compared with the full-length -391/+80, deletion of 85 bp to -306/+80 produced minimal changes in luciferase expression. Deletion of the MEF2 site within the -306/+80 reporter gene resulted in an overall decrease in luciferase expression of 34%. With further deletion of the 5'-flanking sequence to -270/+80, luciferase expression progressively decreased by 60%. Subsequent deletion of a consensus E box (-252/-247) led to a significant (85%) enhancement of luciferase expression. In the presence of neonatal cardiac myocyte nuclear protein, EMSA analysis of the -252 E box demonstrated a shift (Table I) that was competed by 100× wild-type oligonucleotide, but not by 100× mutant oligonucleotide (Fig. 2). The shift was supershifted by antibodies to either USF1 or USF2 and supershifted to a higher molecular weight complex in the presence of both antibodies (Fig. 2A). The data suggest that the -252 E box interacts with USF1 and USF2 and may function as a suppressor of CPT-Ibeta . Deletion of 165 bp of flanking sequence diminishes full-length CPT-Ibeta expression by 50% (-126/+80). This truncation removed one Sp1 site at -136/-131 and a GATA site at -129/-126; deletion of 15 more bp containing a CA box (-117/-112) resulted in a dramatic decrease in reporter gene expression by 90%. Further deletion resulted in partial restoration of activity and an extended deletion produced a minimal promoter containing an Sp-1 site at -74/-68 (Fig. 1).



View larger version (24K):
[in this window]
[in a new window]
 
Fig. 1.   Deletion analysis of the CPT-1beta -391/+80 promoter fragment. Serial deletions of the -391/+80 promoter fragment ligated to the luciferase reporter were transfected into neonatal cardiac myocytes. Transfection reactions included 1.0 µg of reporter and 250 ng of CMV-driven Renilla luciferase expression vector as a control for transfection efficiency. Following transfection, cells were maintained in DMEM containing 10% fetal calf serum for 48 h. Firefly luciferase was normalized to Renilla and is expressed as a ratio multiplied by 100. Bars represent the means ± S.E. of two to three experiments performed in triplicate.



View larger version (47K):
[in this window]
[in a new window]
 
Fig. 2.   Identification of specific transcription factors binding to the CPT-1beta promoter. Protein binding to sequences in the CPT promoter was characterized by gel-mobility shift assay. Oligomers containing binding sites from the CPT-1 promoter were end-labeled with [gamma -32P]ATP and incubated with neonatal rat heart-myocyte, nuclear-protein extracts (see "Experimental Procedures"). Unlabeled competitor oligomers or antibodies were included as indicated above each lane. A, labeled oligomers corresponding to Ebox -252 incubated with rat myocyte nuclear extract (RMNE) and 2 µl of either USF1 or USF2 antibodies or 1 µl of each for a total of 2 µl. B, sequences representing MEF2 -280 incubated with 4 µg of RMNE and MEF2A antibody (2 µl) or with TNT proteins (1 µl of final TNT reaction). C, labeled probes for the Sp1 -74 binding site incubated with 10 µg of RMNE and 2 µl of either Sp1 or Sp3 antibody. D, Labeled oligomers representing GATA-129 and GATA-96 sites incubated with 10 and 15 µg of RMNE, respectively; GATA4 antibodies added as indicated. E, labeled probes for the SRE-112 binding site incubated with 5 µg of RMNE; SRF antibody (2 µl) added as shown.

To examine potential regulatory elements in the context of the intact promoter, mutations were targeted to known sequences contained in the deletion constructs that appear to serve as regulators of CPT-Ibeta expression. The mutated constructs were transfected into neonatal cardiac myocytes for measurement of luciferase expression. In agreement with the deletion data, mutation of the MEF2 site (-280/-271) produced a 46% decrease in reporter gene activity (Fig. 3). Gel mobility-shift assays were conducted to examine nuclear protein binding to double-stranded oligonucleotides corresponding to -280/-271 in the CPT-Ibeta gene. Two bands were shifted and were identical in mobility to TNT-produced proteins corresponding to MEF2C and MEF2A (Fig. 2B). Both bands were competed by 100× wild-type but not 100× mutant oligomers (Fig. 2B), and both were supershifted by antibodies to MEF2. These data suggest that cardiac specificity of CPT-Ibeta expression is partly conferred by the presence of a MEF2 site at the distal end of the promoter construct.



View larger version (21K):
[in this window]
[in a new window]
 
Fig. 3.   Effects of individual site mutations on promoter activity. A model of the protein binding sites indicates the location of the mutated regions. Each region is represented by an X on a labeled line to the left of the results from each separate transfection. Mutated promoter constructs were transfected into rat neonatal cardiac myocytes as described under "Experimental Procedures." Luciferase activity is compared with the wild-type -391/+80 promoter after normalization to protein content and Renilla expression. Bars represent three to five experiments in triplicate reported as means ± S.E. Except for the NKE mutation, all transfections of mutated constructs were significantly different from wild type (10-3 > p > 10-6).

Although mutation of the Sp1 (-137/-131) did reduce CPT-Ibeta expression by 60%, mutations in the CA box (CACCC) at -117/-112 and the Sp1 site (-74/-68) produced strong repression of luciferase expression, i.e. 75% and 76%, respectively (Fig. 3). These data suggest that factors binding to these sites are most likely to be responsible for basal transcription of the CPT-1beta gene. Electrophoretic mobility shift assay of the oligomer containing the -74/-68 region demonstrated two bands, both of which were competed by wild-type oligonucleotide but not by mutant oligomers (Fig. 2C and Table I). Similarly, antibodies to Sp1 and Sp3 abolished formation of the protein/DNA complex (Fig. 2C), suggesting that Sp1 and Sp3 proteins bind to the proximal promoter at -74/-68 and may also play a role in binding to the CA box at -117/-112 (21).

A region flanked by the two Sp1 sites at -137/-131 and -74/-68 contains a cluster of potential cardiac regulatory elements including two GATA binding sites, an SRE, and one potential Nkx site (-94/-88) that partially overlaps with a second GATA binding motif at -96/-93. Mutation of the SRE (-112/-104) results in a 56% decrease in CPT-Ibeta expression in cardiac myocytes (Fig. 3). Serum withdrawal for 44 h dramatically decreases the mRNA concentration of CPT-Ibeta in cardiac myocytes (Fig. 4). This decrease in mRNA content is reversed by replacement of serum-free DMEM with media containing 10% bovine calf serum (Fig. 4), supporting a role for serum-containing factors in the up-regulation of CPT-Ibeta transcription. Mutation of either GATA site results in a 43-38% decrement in gene expression (-129/-126 and - 96/-93, respectively), whereas mutation of both sites (double GATA mutant) causes a slightly greater fall in luciferase activity (55%). The binding of SRF to the SRE (-112/-104) and GATA-4 to the two potential GATA sites at -96/-93 and -129/-126 was confirmed by EMSA (Fig. 2, D and E). Mutation of the Nkx site (-94/-88) has no effect on reporter gene expression in cardiac myocytes (Fig. 3).



View larger version (11K):
[in this window]
[in a new window]
 
Fig. 4.   Quantitative RT-PCR of CPT-1beta transcripts in response to serum deprivation and restoration. Total RNA from rat neonatal cardiac myocytes was isolated and analyzed by quantitative RT-PCR. diamond , freshly isolated myocytes were maintained in DMEM with 10% serum for 12 h. The medium was then removed and replaced with serum-free DMEM for an additional 8, 32, or 44 h. black-diamond , freshly isolated myocytes were placed in serum-free medium immediately after plating for 12, 20, or 44 h. Fresh DMEM with 10% serum was added, and the cells were maintained for an additional 44, 36, or 12 h for a total of 56 h/treatment. Results represent CPT-Ibeta transcripts normalized to cyclophilin mRNA and are presented as mean ± S.E. of triplicate determinations.

Although homeodomain factors achieve specificity via protein binding to DNA, Nkx, SRF, and GATA-4 have been demonstrated to exert regulatory control over cardiac gene expression via protein-protein interactions (11, 22, 23). To study biological activity of these proteins independent of DNA binding, Nkx, GATA-4, and/or SRF expression vectors were cotransfected into CV-1 cells with the full-length CPT-Ibeta reporter gene construct. Transfection of Nkx 2.5 or SRF alone produces modest expression of CPT-Ibeta /luciferase in CV-1 cells (~4-fold activation, Fig. 5). Cotransfection of Nkx and SRF with the promoter gene construct produces additive effects on luciferase expression (Fig. 5A), suggesting that both factors contribute independently to CPT-Ibeta gene activation. GATA-4 transfection alone stimulated CPT-Ibeta 36-fold, making GATA-4 the most potent tissue-specific regulatory element thus far described for this gene. Cotransfection of GATA-4 and Nkx 2.5 with the CPT-Ibeta reporter construct diminished the response of the CPT-Ibeta gene to this combination of factors (Fig. 5B). An additive effect would be predicted if both factors were acting independently. It is possible that Nkx/GATA4 protein-protein interactions (22-24) decreased the amount of GATA4 (and Nkx) available for DNA binding to GATA elements on the CPT-Ibeta gene (25). In contrast to the GATA-4/Nkx cotransfections, coexpression of GATA-4 and SRF produced a synergistic response of the CPT-Ibeta gene (Fig. 5C). This combination of factors resulted in a synergism that was significantly different from the predicted value if the actions of these two proteins were independent. These data provide the first example of a nuclear encoded, cardiac mitochondrial gene where SRF and GATA-4 act as mutual coregulators (11).



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 5.   Combinatorial interactions of Nkx2.5, SRF, and GATA4. Subconfluent CV-1 cells were transfected as described with 1 µg of the -391/+80 CPT-1beta promoter luciferase reporter construct. Total DNA concentrations were adjusted to 2 µg with empty pcDNA vector. A, transfection reactions included 0.4 µg of Nkx2.5 or 0.1 µg of SRF CMV-driven expression vectors alone or in combination. B, the CMV-Nkx2.5 (0.4 µg) and CMV-GATA4 (0.4 µg) expression constructs were used alone or in combination to influence the -391/+80 reporter. C, CMV-driven SRF and GATA4 expression were combined to regulate luciferase expression. Cells were maintained in DMEM with 10% serum for 48 h after transfection and then harvested. Luciferase activity was measured and normalized to total protein concentration and Renilla luciferase. Results are reported as mean ± S.E. of three to five experiments performed in triplicate. Cotransfection of all expression vectors with CPT-Ibeta reporter gene produced significant changes compared with wild type alone. GATA-4 + SRF compared with GATA-4 alone (*, p < 0.002).

To confirm the role of the predicted regulatory domains and protein/DNA interactions in reporter gene expression, point mutations in SRE, the two GATA-4 sites (double mutation) and Nkx2.5 in the -391/+80 CPT-Ibeta construct were cotransfected with SRF or GATA-4 alone or in combination. Mutation of the SRE (and the Nkx), but not of the GATA sites, significantly reduced CPT-Ibeta induction by SRF (Fig. 6A). The induction of CPT-Ibeta reporter expression by GATA-4 alone was significantly reduced by ~50% by all three point mutations (Fig. 6B). The point mutation in the Nkx site (-94/-88) adjacent and overlapping the GATA site likely represents interruption of GATA-4 binding at -96/-93. The remaining reporter gene activity in the presence of the GATA double mutation may represent physical association of the transfected GATA-4 with endogenous factors or basal transcriptional complexes in the CV-1 fibroblasts (11, 25). The combinatorial effects of SRF and GATA4 on the CPT-Ibeta reporter gene were abolished by mutation of either the SRE or the two GATA sites (Fig. 6C). These results reinforce the SRE dependence of these coregulators for synergism (11). Moreover, the results again demonstrate that dramatic induction in CPT-Ibeta gene expression is also regulated in large part by GATA-4 interactions alone, some of which appear independent of binding to traditional GATA sites. The drop in synergism due to the point mutation in the Nkx site (Fig. 6C) appears to reflect a requirement for appropriate flanking sequences to facilitate GATA-4 interaction with the DNA at -96/-93.



View larger version (17K):
[in this window]
[in a new window]
 
Fig. 6.   Induction and synergistic activation of the CPT-1 promoter by SRF and GATA4 is reduced with DNA binding site mutations. Subconfluent CV-1 cells were transfected with 1 µg of wild-type or mutant reporter constructs with expression vectors for SRF and GATA4 alone or in combination. Mutated promoters are schematically represented to the left. Total DNA concentrations were adjusted to 2 µg with empty pcDNA3 vector. Cells were harvested 48 h after transfection, and luciferase activity was recorded and normalized to protein content and Renilla expression. Bars represent mean ± S.E. of three to five experiments in triplicate. Except for the SRF induction of the CPT-Ibeta -GATA double mutant, all results are significantly decreased compared with wild-type reporter activity (0.01 > p > 10-5).

Transfection of a DNA binding mutant SRFpm abolishes the synergistic response between GATA-4 and SRF (Fig. 7). This finding is consistent with requirement for SRF binding to the SRE to produce cardiac alpha  actin promoter coactivation (11). Induction of the GATA-dominated CPT-Ibeta reporter gene expression remains elevated in the presence of transfected GATA-4 and SRFpm. A small reduction in the normal GATA-4 up-regulation may reflect altered affinities of the gene for the SRFpm/GATA-4 complex, including direct binding of the complex to the GATA site(s). A deletion of the C-terminal activation domain of SRF (SRFDelta C) inhibits the combinatorial action of SRF and GATA-4 and dramatically reduces the induction of gene expression due to GATA-4 (Fig. 7). The promoter activation that remains (13-fold) is on the order of induction suggestive of independent GATA binding to the DNA/protein complexes (Fig. 6B, 15-fold induction). The data confirm coactivation of CPT-Ibeta by GATA-4 and SRF that augments the enhancement of gene expression seen in the presence of GATA-4 alone.



View larger version (18K):
[in this window]
[in a new window]
 
Fig. 7.   Disruption of SRF protein structure prevents SRF/GATA4 synergy. Subconfluent CV-1 cells were transfected as described under "Experimental Procedures." Where indicated, expression vectors for wild-type SRF were replaced with 100 ng of either SRF-PM or SRF-Delta C. GATA4 concentrations remained constant (0.4 µg). Cells were harvested after 48 h in serum containing DMEM and luciferase activity measured. Reporter activity was normalized to protein content and Renilla luciferase. Results are presented as mean ± S.E. for three to five experiments performed in triplicate. Both the SRF-PM (*, p < 0.005) and the SRF-Delta C (*, p < 10-4) are significantly decreased compared with the GATA-4 and SRF coinduction of CPT-Ibeta .



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Basal expression of the CPT-Ibeta gene is analogous to the CPT-Ialpha gene in that it contains no TATA box and uses Sp proteins 1 and 3 to drive expression (26). The factors that identify and separate the tissue location of these two isoforms are of particular interest to cardiac muscle where the muscle isoform is dominant, but the liver isoform (CPT-Ialpha ) is also expressed (6). We have identified a region within -391 base pairs of the transcription start site of the muscle isoform that is sufficient to drive CPT-Ibeta transcription and that contains MEF2 and E box elements as well as a cluster of other heart-specific sites. This cluster of CPT-Ibeta regulatory elements is located between -137 and -68 bp of the proximal promoter and includes GATA, Nkx2.5, and SRF DNA-binding sites. Identification of these important cis-trans regulatory domains suggests a multiplicity of pathways that may be expressed and are potentially interactive depending on the CPT-Ibeta gene context and the developmental environment of the myocyte.

The GATA family of transcription factors, represented by heart-specific GATA-4, are potent transactivators of several cardiac promoters. These include atrial natriuretic factor (27), cardiac sarcolemmal Na+,Ca+ exchanger (28), B-type natriuretic peptide (29), and cardiac troponin I (30). GATA-4 (and GATA-6) colocalize in postnatal cardiomyocytes and are believed to act in the differential control of various cellular processes (29). The present results are the first to identify a heart-specific protein, carnitine palmitoyltransferase Ibeta , as a downstream mitochondrial target of GATA-4. Two GATA binding sites are present in this gene although transcriptional activation by GATA does not always require DNA binding (25). Together with Nkx 2.5, GATA-4 has been demonstrated to be a powerful transcriptional coactivator of the ANF promoter (31) and the cardiac alpha  actin promoter (23). In the context of the CPT-Ibeta gene, however, coexistence of GATA-4 and Nkx 2.5 decreases reporter gene expression in CV-1 cells. Compared with a significant, but small, transactivation by Nkx 2.5, GATA-4 expression in CPT-Ibeta -transfected CV-1 cells produces a greater than 30-fold increase in CPT-Ibeta gene reporter activity, indicating GATA domination of the CPT-Ibeta promoter. Nkx 2.5 may act to sequester GATA factors away from GATA-binding sites in GATA-dependent promoters (25). A DNA-independent interaction between GATA and Nkx 2.5 could therefore remove GATA-4 from its interaction sites in CPT-Ibeta , resulting in the decreased reporter gene expression observed.

In cardiac myocytes, the double GATA site mutation reduces reporter gene expression by greater than 50%, supporting the importance of DNA binding in the cumulative GATA effects. Cotransfection of the reporter gene with the double GATA mutant into CV-1 cells also reduces reporter gene expression by GATA-4 by 43%, but significant gene induction is still retained. These data again suggest that GATA-4 may also influence CPT-Ibeta gene expression by protein-protein interactions, interacting with endogenous levels of factors that affect basal transcription (25). Among these factors, SRF has recently been shown to be a mutual coregulator with GATA-4 in numerous myogenic SRE-dependent promoters (11). In the absence of GATA-DNA binding, SRF binds to the CArG box sequence and physically associates with GATA-4 through the MADS box of SRF and the second zinc finger domain of GATA-4 (11). In the CPT-Ibeta promoter, the presence of serum has dramatic effects on CPT-Ibeta mRNA content in the neonatal myocyte cultures. SRF binds to one SRE (-112/-104), and mutation of this site also dramatically decreases CPT-Ibeta reporter gene expression. Although cotransfection of SRF with CPT-Ibeta has small inductive effects comparable to those seen with Nkx 2.5, the presence of GATA-4 factors synergistically activates CPT-Ibeta to levels that are significantly greater than expression of GATA-4 and SRF independently. The data suggest that even in a background of high GATA-4-induced gene expression, SRF binding to SRE and association with GATA-4 is a quantitatively important mechanism to up-regulate further expression of the muscle isoform of CPT-I. It is possible that the postnatal expression of CPT-Ibeta is dependent on the presence of serum factors and GATA-4 interacting physically and functionally to increase the myocardial content of this isoform to adult levels (6). Supporting a possible physiological importance of this mechanism, we have demonstrated that electrical stimulation of neonatal cardiac myocytes in culture induces CPT-Ibeta mRNA accumulation (3) subsequent to up-regulation of GATA-4 gene expression (5).

A requirement for MEF2 in CPT-Ibeta gene expression is consistent in the known role for the MEF2 proteins in the differentiation of muscle cell lineages. MEF2 has also been reported to mediate hypertrophic signaling as well as synergistic transcriptional responses (32). These pathways gain additional significance in the heart where cardiac hypertrophy and failure is linked to down-regulation of the enzymes of the beta -oxidation pathway (33), including CPT-Ibeta (34). The CPT-Ibeta promoter contains a MEF2/DNA binding site, and mutational analysis reveals a 46% depression in CPT-Ibeta gene expression when the MEF2 site is mutated. Nuclear protein extracts of the neonatal cardiac myocytes demonstrate binding of both MEF2A and MEF2C in electrophoretic mobility shift assays. The ability of the MEF2 proteins to activate transcription in vivo depends on the dimer composition of the binding complex and the cellular context.

Twenty base pairs downstream of the MEF2 binding element, we have identified an E box that acts as a suppressor of CPT-Ibeta in the promoter deletion analysis. The consensus E box binds basic helix-loop-helix regulatory proteins and are contained in the regulatory regions of most developmentally controlled, muscle-specific genes. In the CPT-Ibeta gene, we have identified the E box-binding proteins as the upstream stimulatory factors, USF1 and USF2. Although a role for rat USF1 has been suggested in contractile-mediated activation of alpha  myosin heavy chain gene (35), USF can either positively or negatively regulate promoter activity via independent cis regulatory elements (36). E boxes are also frequently associated with adjacent MEF2 sites with a spacing that promotes protein-protein interaction between E box and MEF2 basic helix-loop-helix factors bound to the DNA. The interaction of this E box site with MEF2 and adjacent sites in the promoter is currently under investigation.

Finally, the presence of a FARE site in the rat CPT-Ibeta promoter has been confirmed by these studies. The activity of this site in our hands produces a small induction of CPT-Ibeta gene expression (2-3-fold) at high physiological concentrations of oleate (2:1 molar ratio) in the cell medium. This fold induction is less than previously reported at a 7:1 oleate to albumin molar ratio (8-20-fold) (7). Although a role for fatty acids in the induction of CPT-Ibeta gene transcription is an attractive regulatory mechanism physiologically, other studies have not been able to demonstrate a role for elevated serum fatty acids in altering the cardiac content of CPT-Ibeta mRNA and protein (9, 10). These studies suggest that, like other heart-specific proteins, CPT-Ibeta contains the same pattern of muscle-specific control regions. Its expression in the heart is likely GATA-4-dominated and is subject to protein-protein interactions that can regulate its expression in a manner that is context-dependent. Interestingly, these studies also verify that gene expression of a major controlling enzyme in mitochondrial oxidative metabolism is coordinate with expression of proteins important in contractile function and energy consumption.


    FOOTNOTES

* This work was supported by National Institutes of Health Grants RO1 HL38863 (to J. B. M.) and PO1-HL49953 (to R. J. S.), and by United States Department of Agriculture Grant ARS6250-6100 (to R. J. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of Pathology and Laboratory Medicine, Medical School, University of Texas-Houston Health Science Center, 6431 Fannin, Houston, TX 77030. Tel.: 713-500-5335; Fax: 713-500-0730; E-mail: jeanie.b.mcmillin@uth.tmc.edu.

Published, JBC Papers in Press, October 18, 2000, DOI 10.1074/jbc.M009352200


    ABBREVIATIONS

The abbreviations used are: CPT-I, carnitine palmitoyltransferase I; CMV, cytomegalovirus; EMSA, electrophoretic mobility shift assay; PCR, polymerase chain reaction; bp, base pair(s); FARE, fatty acid response element; SRF, serum response factor; SRE, serum response element; DMEM, Dulbecco's modified Eagle's medium; USF, upstream stimulatory factor; RMNE, rat myocyte nuclear extract; TNT, transcription/translation.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Virbasius, C. A., Virbasius, J. V., and Scarpulla, R. C. (1993) Genes Dev. 7, 2431-2445[Abstract]
2. Virbasius, J. V., Virbasius, C. A., and Scarpulla, R. C. (1993) Genes Dev. 7, 380-392[Abstract]
3. Xia, Y., Buja, L. M., Scarpulla, R. C., and McMillin, J. B. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 11399-11404[Abstract/Free Full Text]
4. Lenka, N., Vijayasarathy, C., Mullick, J., and Avadhani, N. G. (1998) Prog. Nucleic Acids Res. Mol. Biol. 61, 309-344[Medline] [Order article via Infotrieve]
5. Xia, Y., McMillin, J., Lewis, A., Moore, M., Zhu, W. G., Williams, R. S., and Kellems, R. E. (2000) J. Biol. Chem. 275, 1855-1863[Abstract/Free Full Text]
6. Esser, V., Brown, N. F., Cowan, A. T., Foster, D. W., and McGarry, J. D. (1996) J. Biol. Chem. 271, 6972-6977[Abstract/Free Full Text]
7. Brandt, J.M., Djouadi, F., and Kelly, D. P. (1998) J. Biol. Chem. 273, 23786-23792[Abstract/Free Full Text]
8. Djouadi, F., Brandt, J. M., Weinheimer, C. J., Leone, T. C., Gonzalez, F. J., and Kelly, D. P. (1999) Prostaglandins Leukotrienes Essent. Fatty Acids 60, 339-343[CrossRef][Medline] [Order article via Infotrieve]
9. Mynatt, R. L., Lappi, M. D., and Cook, G. A. (1992) Biochim. Biophys. Acta 1128, 105-111[Medline] [Order article via Infotrieve]
10. Cook, G. A. (1984) J. Biol. Chem. 259, 12030-12033[Abstract/Free Full Text]
11. Belaguli, N. S., Sepulveda, J. L., Nigam, V., Charron, F., Nemer, M., and Schwartz, R. J. (2000) Mol. Cell. Biol. 20, 7550-7558[Abstract/Free Full Text]
12. Arsenian, S., Weinhold, M., Oelgeschlager, M., Ruther, U., and Nordheim, A. (1998) EMBO J. 17, 6289-6299[Abstract/Free Full Text]
13. Belaguli, N. S., Schildmeyer, L. A., and Schwartz, R. J. (1997) J. Biol. Chem. 272, 18222-18231[Abstract/Free Full Text]
14. Browning, C. L., Culberson, D. E., Argon, I. V., Fillmore, R. A., Croissant, J. D., Schwartz, R. J., and Zimmer, W. E. (1998) Dev. Biol. 194, 18-37[CrossRef][Medline] [Order article via Infotrieve]
15. Croissant, J. D., Kim, J. H., Eichele, G., Goering, L., Lough, J., Prywes, R., and Schwartz, R. J. (1996) Dev. Biol. 177, 250-264[CrossRef][Medline] [Order article via Infotrieve]
16. McMillin, J. B., Hudson, E. K., and Buja, L. M. (1993) Methods Toxicol. 2, 301-309
17. Muller, M. M., Schreiber, E., Schaffer, W., and Matthius, P. (1989) Nucleic Acids Res. 17, 6420[Medline] [Order article via Infotrieve]
18. Wang, D., Harrison, W., Buja, L. M., Elder, F. F. B., and McMillin, J. B. (1998) Genomics 48, 314-323[CrossRef][Medline] [Order article via Infotrieve]
19. Depre, C., Shipley, G. L., Chen, W., Han, Q., Doenst, T., Moore, M., Stepkowski, S., Davies, P. J. A., and Taegtmeyer, H. T. (1998) Nat. Med. 11, 1269-1275[CrossRef]
20. Sack, M. N., Disch, D. L., Rockman, H., and Kelly, D. P. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 6438-6443[Abstract/Free Full Text]
21. Zhao, J. L., Austen, K. L., and Lam, B. K. (2000) J. Biol. Chem. 275, 8903-8910[Abstract/Free Full Text]
22. Chen, C. Y., and Schwartz, R. J. (1996) Mol. Cell Biol. 16, 6372-6384[Abstract]
23. Sepulveda, J. L., Belaguli, N., Nigam, V., Chen, C.-H., Nemer, M., and Schwartz, R. J. (1998) Mol. Cell Biol. 18, 3405-3415[Abstract/Free Full Text]
24. Durocher, D., and Nemer, M. (1998) Dev. Genet. 22, 250-262[CrossRef][Medline] [Order article via Infotrieve]
25. Shiojima, I., Komuro, I., Oka, T., Hiroi, Y., Mizuno, T., Takimoto, E., Monzen, K., Aikawa, R., Akazawa, H., Yamazaki, T., Kudoh, S., and Yazaki, Y. (1999) J. Biol. Chem. 274, 8231-8239[Abstract/Free Full Text]
26. Steffen, M. L., Harrison, W. R., Elder, F. F. B., Cook, G. A., and Park, E. A. (1999) Biochem. J. 340, 425-432[CrossRef][Medline] [Order article via Infotrieve]
27. Lee, Y., Shioi, T., Kasahara, H., Jobe, S. M., Wiese, R. J., Markham, B. E., and Izumo, S. (1998) Mol. Cell Biol. 18, 3120-3129[Abstract/Free Full Text]
28. Nicholas, S. B., and Philipson, K. D. (1999) Am. J. Physiol. 277, H324-H330[Medline] [Order article via Infotrieve]
29. Charron, F., Paradis, P., Bronchain, O., Nemer, G., and Nemer, M. (1999) Mol. Cell. Biol. 19, 4355-5365[Abstract/Free Full Text]
30. Bhavsar, P. K., Dellow, K. A., Yacoub, M. H., Brand, N. J., and Barton, P. J. (2000) J. Mol. Cell. Cardiol. 32, 95-108[CrossRef][Medline] [Order article via Infotrieve]
31. Durocher, D., Charron, F., Warren, R., Schwartz, R. J., and Nemer, M. (1997) EMBO J. 16, 5687-5696[Abstract/Free Full Text]
32. Lu, J., McKinsey, T. A., Nicol, R. L., and Olson, E. N. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 4070-4075[Abstract/Free Full Text]
33. Sack, M. N., Rader, T. A., Park, S., Bastin, J., McCune, S. A., and Kelly, D. A. (1996) Circulation 94, 2837-2842[Abstract/Free Full Text]
34. Leone, T. C., Weinheimer, C. J., and Kelly, D. P. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 7473-7478[Abstract/Free Full Text]
35. Xiao, Q., and Ojamaa, K. (1998) J. Mol. Cell. Cardiol. 30, 87-95[CrossRef][Medline] [Order article via Infotrieve]
36. Navankasattusas, S., Sawadogo, M., van Bilsen, M., Dang, C. V., and Chien, K. R. (1994) Mol. Cell. Biol. 14, 7331-7339[Abstract]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.